Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius Medical Care AG & Co. KGaA

Division of Fresenius SE & Co. KGaA
www.fmc-ag.com

Latest From Fresenius Medical Care AG & Co. KGaA

Cara Therapeutics' Stock Buoyed By Positive Korsuva Data For Post-Op Pain

Cara Therapeutics will discuss its options with regulators after positive top-line data from adaptive Phase II/III trial of its Korsuva drug in patients undergoing abdominal surgeries met its prime endpoint and sent the biotech's stock higher.

Clinical Trials Companies

Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017

Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.

Medical Device In Vitro Diagnostics

MTI 100: Medtronic Still Leads, While M&A, Strategic Moves Elevate Others

After knocking Johnson & Johnson off its long-held top position last year, Medtronic has successfully retained the lead in the global medtech market for the second year running in Medtech Insight's MTI 100 rankings. Meanwhile, movement and reshuffling in the ranks continued among other top-tier industry players as they reaped the rewards from previous M&A deals and long-term growth strategies. In this article, we take a closer look at the top-10 overall players, and see who's leapt in front of rivals and who's left eating dust in Medtech Insight's 2017 edition of its annual ranking.

Medical Device Commercial

Options For Medtechs In A Value-Based Care World

Driven by increasingly cost-conscious payers, health care is shifting from a volume-based model to “value-based care,” now the latest buzzword. In response, the medical device industry has started employing new commercial strategies.

Market Access Medical Device
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register